Skip to main content
TipRanks
Go Ultimate75% OFF

Annovis Bio (ANVS) Stock Statistics & Valuation Metrics

766 Followers

Total Valuation

Annovis Bio has a market cap or net worth of $39.53M. The enterprise value is $51.32M.

Market Cap
$39.53M
Enterprise Value
$51.32M

Share Statistics

Annovis Bio has 42,679,058 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
42,679,058
Owned by Insiders
20.12%
Owned by Institutions
9.95%

Financial Efficiency

Annovis Bio’s return on equity (ROE) is -1.71 and return on invested capital (ROIC) is -170.21%.

Return on Equity (ROE)
-1.71
Return on Assets (ROA)
-1.37
Return on Invested Capital (ROIC)
-170.21%
Return on Capital Employed (ROCE)
-1.70
Revenue Per Employee
0
Profits Per Employee
-4.12M
Employee Count
7
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Annovis Bio is -0.56. Annovis Bio’s PEG ratio is 0.03.

PE Ratio
-0.56
PS Ratio
0.00
PB Ratio
-0.00
Price to FCF
-0.71
Price to Operating Cash Flow
-0.71
PEG Ratio
0.03

Income Statement

In the last 12 months, Annovis Bio had revenue of 0 and earned -28.85M in profits. Earnings per share was -1.40.

Revenue
0
Gross Profit
0
Operating Income
-29.70M
Pretax Income
-28.85M
Net Income
-28.85M
EBITDA
-28.85M
Earnings Per Share (EPS)
-1.40

Cash Flow

In the last 12 months, operating cash flow was -55.89M and capital expenditures 4, giving a free cash flow of -55.89M billion.

Operating Cash Flow
-55.89M
Free Cash Flow
-55.89M
Free Cash Flow per Share
-1.31

Dividends & Yields

Annovis Bio pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-141.40%
Earnings Yield
-131.00%

Stock Price Statistics

Beta
2.63
52-Week Price Change
-59.56%
50-Day Moving Average
1.10
200-Day Moving Average
1.80
Relative Strength Index (RSI)
45.72
Average Volume (3m)
1.73M

Important Dates

Annovis Bio upcoming earnings date is Apr 06, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 13, 2026
Next Earnings Date
Apr 06, 2027
Ex-Dividend Date
―

Financial Position

Annovis Bio as a current ratio of 5.80, with Debt / Equity ratio of 0.00%

Current Ratio
5.80
Quick Ratio
5.80
Debt to Market Cap
0.00
Net Debt to EBITDA
0.68
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Annovis Bio has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Annovis Bio EV to EBITDA ratio is 47.30, with an EV/FCF ratio of 49.75.

EV to Sales
0.00
EV to EBITDA
47.30
EV to Free Cash Flow
49.75
EV to Operating Cash Flow
49.75

Balance Sheet

Annovis Bio has $2.82B in cash and marketable securities with $0.00 in debt, giving a net cash position of $2.82B billion.

Cash & Marketable Securities
$2.82B
Total Debt
$0.00
Net Cash
$2.82B
Net Cash Per Share
$66.07
Tangible Book Value Per Share
-$310.41

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Annovis Bio is $9.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$9.33
Price Target Upside
907.92% Upside
Analyst Consensus
Strong Buy
Analyst Count
3
Revenue Growth Forecast
―
EPS Growth Forecast
-15.00%

Scores

Smart Score
10
AI Score
42